Immune response modifier compounds for treatment of TH2 mediated and related diseases
US6039969A · kind A · utility
284Cited by
13References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 24, 1997 |
| Grant date | Mar 21, 2000 |
| Priority date | — |
| Expiry date | Oct 24, 2017 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Immune response modifier compounds--imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, and 1,2-bridged imidazoquinoline amines--are useful for the treatment of TH2 mediated diseases by administering a therapeutically effective amount of such compounds in order to inhibit TH2 immune response, suppress IL-4/IL-5 cytokine induction and eosinophilia, as well as enhance TH1 immune response.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.